Postmarketing trials may help alleviate the US FDA's concerns about the long-term use of a high dose of Pfizer Inc.'s Xeljanz (tofacitinib) in ulcerative colitis (UC).
FDA's May 30 approval of the product in UC made the JAK inhibitor the first oral therapy marketed for the indication in the US. EMA's Committee for Medicinal Products...